Nicorette Invisi Patch relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. Nicorette Invisi Patch is indicated in pregnant and lactating women making a quit attempt (see section 4.6). If possible, Nicorette Invisi Patch should be used in conjunction with a behavioural support programme.
The FDA has granted Orphan Status approval for PermaDerm, from Regenicin, the first tissue-engineered skin prepared from autologous skin cells...
Objective: To define and compare inflammatory protein biomarkers of HS and psoriasis skin.
Durata Therapeutics, Inc. has announced that it has submitted a New Drug Application (NDA) to the FDA seeking approval for...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tenkasi (oritavancin) from Menarini International Operations Luxembourg S.A.
Motif Bio plc announced that the Company has received a Complete Response Letter (CRL) from the FDA regarding the New...
Introduction: In psoriasis clinical trials, treatment success is often defined as achieving a static Physician Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). Patients with clear versus almost clear skin may experience psoriasis differently.